Equasens: 2024 nine-month revenue: €158.2 million - Return to growth in Q3 (+0.3%)
07 Novembre 2024 - 6:00PM
UK Regulatory
Equasens: 2024 nine-month revenue: €158.2 million - Return to
growth in Q3 (+0.3%)
Villers-lès-Nancy, 7 November 2024 - 6:00 p.m.
(CET)
PRESS RELEASE
2024 nine-month revenue:
€158.2 million
Return to growth
in Q3 (+0.3%)
|
Revenue (€m) |
2023
Reported basis |
2024
Reported basis |
Change /
Reported basis |
- Ségur
2024 |
+Ségur
2023 |
- External Growth
|
Change /
Like-for-like basis |
|
Q1 |
56.2 |
53.3 |
-2.9 |
-5.2% |
0.3 |
1.4 |
2.0 |
-3.8 |
-6.7% |
|
Q2 |
56.4 |
54.7 |
-1.7 |
-3.0% |
0.3 |
1.2 |
1.7 |
-2.6 |
-4.6% |
|
Q3 |
50.1 |
50.2 |
0.1 |
0.3% |
0.2 |
0.3 |
1.8 |
-1.5 |
-3.0% |
|
Total |
162.7 |
158.2 |
-4.5 |
-2.8% |
0.9 |
2.9 |
5.5 |
-7.9 |
-4.9% |
At September 30, 2024, Equasens
Group reported year-to-date revenue of €158.2m, down 2.8%
on a reported basis from one year earlier and 4.9%
like-for-like.
- Improved momentum
in Q3 both on a reported and like-for-like basis, with renewed
growth by all divisions except AXIGATE LINK which has been growing
since the beginning of the year.
- Stable
contributions from acquisitions, up 3.5% in the quarter.
Operating highlights:
|
Year-to-date revenue at 30 September by business
(€m) |
2023
Reported basis |
2024
Reported basis |
Change / Reported basis |
|
Sale of configurations and hardware |
70.3 |
62.7 |
-7.5 |
-10.7% |
|
Scalable maintenance and professional training services |
58.3 |
60.5 |
2.2 |
3.8% |
|
Software solutions and subscriptions |
32.2 |
33.0 |
0.8 |
2.6% |
|
Other services (including intermediation) |
1.9 |
1.9 |
0.0 |
-0.7% |
|
TOTAL |
162.7 |
158.2 |
-4.5 |
-2.8% |
- A smaller decline
in configuration and hardware sales (-5.0% in Q3
alone, compared with -12.9% in H1) in the Pharmagest and e-Connect
Divisions.
- Scalable
maintenance services and business training continue to
grow, albeit at a slower pace (+0.5% in Q3 2024), while e-learning
sales are down.
- The
software solutions and subscriptions business
registered strong growth (+11.4% in Q3 compared with -0.9% in H1),
with a significantly smaller Ségur base effect (€0.1m).
Acquisitions in 2024 also significantly contributed to the
segment's growth.
|
Year-to-date revenue at 30/09 / Division (€m) |
2023
Reported basis |
2024
Reported basis |
Change /
Reported basis |
- Ségur
2024 |
+Ségur
2023 |
- External Growth |
Change /
Like-for-like basis |
|
Pharmagest |
120.5 |
120.1 |
-0.4 |
-0.4% |
0.4 |
1.4 |
5.4 |
-4.9 |
-4.0% |
|
Axigate Link |
22.3 |
22.6 |
0.3 |
1.5% |
0.2 |
0.9 |
|
1.0 |
4.7% |
|
e-Connect |
11.7 |
8.3 |
-3.5 |
-29.5% |
|
|
|
-3.5 |
-29.5% |
|
Medical Solutions |
6.7 |
5.8 |
-1.0 |
-14.2% |
0.2 |
0.6 |
0.1 |
-0.7 |
-10.0% |
|
Fintech |
1.5 |
1.5 |
0.0 |
1.6% |
|
|
|
0.0 |
1.6% |
|
Total |
162.7 |
158.2 |
-4.5 |
-2.8% |
0.9 |
2.9 |
5.5 |
-7.9 |
-4.9% |
- The PHARMAGEST
Division ended Q3 2024 with revenue of €38.0m, up 3.2% on
Q3 2023 and marginally down year-to-date (-0.4% to
€120.1m).
- In France, with
revenue up 0.9% over the quarter and 2.7% year-to-date
respectively, business was notably driven by software solutions and
subscriptions (+62.6% in Q3), with acquisitions in 2024
contributing €1.0m in the quarter.
- Configuration and
hardware sales remain down (-1.6% in Q3) with the electronic label
market remaining sluggish (-€0.7m).
- In the rest of
Europe, growth remained strong, gaining 24.0% in the quarter and
19.8% year-to-date. Italy contributed significantly to this good
performance (+7.5% in Q3) while PHARMAGEST Germany added €0.7m to
revenue for the quarter and €2.2m year-to-date.
This Division accounts for 75.9% of total
revenue.
- The AXIGATE LINK
Division recorded revenue in Q3 of €7.2m, down
2.7% compared with Q3 2023. For the first nine months, the Division
reported growth in revenue of 1.5% to €22.6m. The
Division now equips 4,381 health and medico-social establishments
with a net increase of 51 new customers since the beginning of
2024.
- Continuing growth
of the nursing home sector, which accounts for 53% of the
Division's sales, has been driven by the deployment of TITAN LINK
in France (558 establishments out of 2,500 customer sites) and
Belgium (73 establishments out of 919 customer sites). Its launch
in the UK is scheduled for the end of 2024 and is expected to
contribute to accelerating the division's future growth.
- Growth momentum of
the Homecare sector (21% of the Division's revenue) also remains on
track, as DICSIT expand its coverage to Territorial Resource
Centres, regional entities that help the elderly remain in their
homes as long as possible, with the upcoming launch of a specially
designed, innovative solution.
- The Hospital sector
(12% of the Division's revenue) remains buoyant, with the signature
of two major contracts with large psychiatric establishments for
orders totalling nearly €1m to be deployed mainly in 2025. In
addition, the customer portfolio was strengthened in Q3 by the
addition of two new medium-sized hospitals.
This Division accounts for 14.3% of total
revenue.
- The E-CONNECT
Division had Q3 revenue of €2.8m, down 23.2% from Q3 2023
and bringing the decline for the first nine months to
29.5%, compared with 32.3% in H1 2024.
- As a reminder: the
Division experienced exceptional growth in 2023 driven by a
regulatory windfall (i.e. the announcement of the discontinuation
of Application Reader Terminal sales).
- Against the
backdrop of a persistently difficult market, the Division
integrated new software publishers for its Kap-inSide and eS-Kap+
solutions which address all mobility needs of healthcare
professionals (billing at the patient's bedside), thereby
significantly expanding its potential customer base.
- Marketing of the
KAP-eCV (the electronic French health insurance card reader) has
begun in the test departments. In this initial phase, the KAP-eCV
was selected by more than 25 major software publishers covering
more than half of France's healthcare professionals, confirming the
strong potential linked to the nationwide roll-out plan of the
French National Health Insurance administration to begin in January
2025.
- The NOVIAcare offer
is being adopted by new tele-care providers in France and is
continuing to be rolled out in the Netherlands.
This Division accounts for 5.2% of total
revenue.
- The MEDICAL SOLUTIONS
Division had Q3 revenue of €1.8m, down slightly (-1.2%) on
Q3 2023, bringing the decline for the first 9 months
to -14.2% compared with -19.1% in H1 2024.
- Q3 was marked by
the finalisation of investments to develop new offerings due to be
launched over the next 6 months. These include LOQuii, the
consultation voice assistant, MS.SAFE, the online backup solution,
and the Agenda, enabling patients to book appointments online from
early 2025. In this way, the Division is strengthening its upsell
strategy to provide growth drivers and recurring revenues.
- In addition, the
successful deployment in September of an intermediation offer with
a major pharmaceutical player confirms MédiStory's potential as a
software solution for prevention and patient support, opening up
new growth prospects for this activity in 2025.
The Division accounts for 3.6% of total
revenue.
- The FINTECH
Division reported revenue of €0.4m for Q3 2024 and
€1.5m for the first nine months, in line with the performances for
the same periods in 2023.
- A highlight of Q3
included the launch of the new Dispay bankcard payment service,
integrated into the healthcare professional's management
software.
- While the
contribution to revenue is still marginal at this stage, the
Division remains confident that will be able to generate additional
revenue as its customer base expands.
2024 outlook
- Equasens Group
remains confident that growth will be back on track in Q4
2024.
- The Group is
continuing to actively explore opportunities for external growth in
France and Europe, in order to strengthen its position in its
markets.
Financial
calendar:
- Q4 2023 revenue: 6 February
2025
About
Group Equasens
With more than 1,300 employees, Equasens
Group is today a key player in the European healthcare sector,
providing software and hardware solutions to all healthcare
professionals (pharmacists, primary care practitioners, hospitals,
hospital-at-home programmes, retirement homes, health centres) in
both primary and secondary care sectors.
With operations in in France, Germany, Great
Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group
today brings together healthcare professionals within a unique
ecosystem in France and Europe benefiting people by making
available the very best of technology.
Listed on Euronext Paris™ - Compartment
B
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index
2020 - CAC® SMALL and
CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European
Rising Tech label
Eligible for the Deferred Settlement Service (“Service à
Règlement Différé” - SRD) and equity savings accounts invested in
small and mid-caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code:
EQS
Get all the news about Equasens
Group www.equasens.com
and on
LinkedIn
CONTACTS
Analyst and Investor
Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com
Financial communications
agency:
FIN’EXTENSO - Isabelle Aprile
Tel.: +33 (0)6 17 38
61 78 - i.aprile@finextenso.fr
- EQUASENS_PRESS RELEASE_20241107_Sales Q3_2024_V2_EN_GB
Equasens (EU:EQS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Equasens (EU:EQS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
